Also, the specific investigation of APOE4 carriers, and also limiting the analysis to individuals with high cerebral β-amyloid (Aβ+ vs. Aβ−), and effects associated with tau progression beyond the entorhinal cortex, may provide additional insights on AD pathology (Braak and Braak, 1991b; Thal et al., 2002). This evidence concerns the gene MAPT and Alzheimer disease.